A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)

Publisher： Karger

E-ISSN： 1423-0232|91|1|24-30

ISSN： 0030-2414

Source： Oncology, Vol.91, Iss.1, 2016-05, pp. : 24-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

By  

Oncology, Vol. 83, Iss. 3, 2012-08 ,pp. : 151-157

Karger

Access to resources Recommend Favorite

A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 317-322

Karger

Access to resources Recommend Favorite

A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 88, Iss. 6, 2015-0 ,pp. : 353-359

Karger

Access to resources Recommend Favorite

Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer

By  

Oncology, Vol. 89, Iss. 3, 2015-05 ,pp. : 152-158

Karger

Access to resources Recommend Favorite

Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 113-119

Karger

Access to resources Recommend Favorite